indazoles has been researched along with bmn 673 in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (52.94) | 24.3611 |
| 2020's | 8 (47.06) | 2.80 |
| Authors | Studies |
|---|---|
| André, F; Ashworth, A; Bajrami, I; Dorvault, N; Elliott, R; Fontebasso, Y; Friboulet, L; Lord, CJ; Olaussen, KA; Postel-Vinay, S; Soria, JC | 1 |
| Konstantinopoulos, PA; Liu, JF; Matulonis, UA | 1 |
| DiGiammarino, EL; Donawho, CK; Gao, W; Hopkins, TA; Johnson, EF; Maag, D; Olson, AM; Osterling, DJ; Panchal, SC; Rodriguez, LE; Shi, Y; Solomon, LR; Stolarik, DF; Wilsbacher, JL | 1 |
| Seimiya, H | 1 |
| Cohen, MS; Ekblad, T; Karlberg, T; Löw, M; Moche, M; Pinto, AF; Schüler, H; Thorsell, AG; Trésaugues, L | 1 |
| Gillard, M; Lee, JM; Lipkowitz, S; Zimmer, AS | 1 |
| Al-Kawaz, A; Ali, R; Band, V; Green, AR; Madhusudan, S; Mesquita, KA; Miligy, IM; Mirza, S; Rakha, EA; Seedhouse, C; Toss, MS | 1 |
| Coleman, RL; Kurnit, KC; Westin, SN | 1 |
| Balmaña, J; Castroviejo-Bermejo, M; Cruz, C; de Bono, JS; Kaye, SB; Lord, CJ; Mateo, J; Oaknin, A; Serra, V; Tutt, A | 1 |
| Cui, M; Han, L; Wang, L; Wang, Q; Xu, Y | 1 |
| Amaravadi, RK; Bast, RC; Becker, SE; Heinzen, EP; Hou, X; Llombart-Cussac, A; Lu, Z; Matias-Guiu, X; Maurer, MJ; Oberg, AL; Pang, L; Poveda, A; Rask, P; Romero, I; Rubio, MJ; Santacana, M; Santiago-O'Farrill, JM; Weroha, SJ | 1 |
| Al-Lazikani, B; Ameratunga, M; Antolin, AA; Banerji, U; Clarke, PA; Workman, P | 1 |
| Distel, LV; Fietkau, R; Hecht, M; Heinzerling, L; Jost, T; Knippertz, I; Weigert, V | 1 |
| Luger, K; Roberts, G; Rudolph, J | 1 |
| Distel, L; Fietkau, R; Gajdošová, F; Hecht, M; Jonuscheit, S; Jost, T; Wrobel, M | 1 |
| Cai, Z; Cao, D; Chang, C; Jiang, Z; Liu, C; Mu, M; Shen, C; Yin, X; Yin, Y; Zhang, B; Zhang, L; Zhao, Z | 1 |
| Azaïs, H; Bats, AS; Bentivegna, E; Blons, H; Delanoy, N; Durdux, C; Koual, M; Laurent-Puig, P; Le Frère-Belda, MA; Le Gac, M; Nguyen-Xuan, HT; Perkins, G | 1 |
8 review(s) available for indazoles and bmn 673
| Article | Year |
|---|---|
PARP inhibitors in ovarian cancer: current status and future promise.
Topics: Antineoplastic Agents; Benzimidazoles; DNA Repair; Female; Genes, BRCA1; Genes, BRCA2; Humans; Indazoles; Indoles; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors | 2014 |
[Cancer therapy by PARP inhibitors].
Topics: Antineoplastic Agents; Benzimidazoles; BRCA1 Protein; BRCA2 Protein; DNA Breaks, Double-Stranded; DNA Replication; DNA, Single-Stranded; Enzyme Inhibitors; Humans; Indazoles; Indoles; Molecular Targeted Therapy; Mutation; Neoplasms; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Recombinational DNA Repair | 2015 |
Update on PARP Inhibitors in Breast Cancer.
Topics: BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Female; Humans; Indazoles; Indoles; Neoplasm Recurrence, Local; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Progression-Free Survival | 2018 |
Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; BRCA1 Protein; BRCA2 Protein; Carbazoles; Carcinoma, Ovarian Epithelial; Female; Humans; Indazoles; Indoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Ovary; Phthalazines; Phthalimides; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors | 2018 |
A decade of clinical development of PARP inhibitors in perspective.
Topics: BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Female; Genomic Instability; Humans; Indazoles; Indoles; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors | 2019 |
Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance.
Topics: Antineoplastic Agents; Benzimidazoles; BRCA1 Protein; BRCA2 Protein; Carcinoma, Ovarian Epithelial; DNA Repair; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Indoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases | 2020 |
Comparative safety and tolerability of approved PARP inhibitors in cancer: A systematic review and network meta-analysis.
Topics: Humans; Indazoles; Indoles; Neoplasms; Network Meta-Analysis; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Randomized Controlled Trials as Topic | 2021 |
[Place of PARP inhibitors in the treatment of endometrial and cervical cancers].
Topics: Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Clinical Trials as Topic; DNA Damage; DNA Repair-Deficiency Disorders; Endometrial Neoplasms; Female; Humans; Indazoles; Indoles; Ovarian Neoplasms; Papillomavirus Infections; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Uterine Cervical Neoplasms | 2022 |
9 other study(ies) available for indazoles and bmn 673
| Article | Year |
|---|---|
A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Line, Tumor; DNA Breaks, Double-Stranded; DNA Repair; DNA-Binding Proteins; Endonucleases; Enzyme Inhibitors; G2 Phase Cell Cycle Checkpoints; High-Throughput Screening Assays; Humans; Indazoles; Lung Neoplasms; Phthalazines; Piperazines; Piperidines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Protein Isoforms; Rad51 Recombinase; RNA Interference; RNA, Small Interfering | 2013 |
Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors.
Topics: Animals; Antineoplastic Agents, Alkylating; Benzimidazoles; Cell Line; Cell Line, Tumor; DNA Damage; DNA Repair; DNA-Binding Proteins; Drug Tolerance; Humans; Indazoles; Mice; Neoplasms, Experimental; Phthalazines; Piperazines; Piperidines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases | 2015 |
Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors.
Topics: Animals; Benzimidazoles; Enzyme Inhibitors; HEK293 Cells; Humans; Indazoles; Models, Molecular; Phenanthrenes; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Tankyrases | 2017 |
Targeting PARP1 in XRCC1-Deficient Sporadic Invasive Breast Cancer or Preinvasive Ductal Carcinoma
Topics: Apoptosis; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Cell Cycle; Cell Line, Tumor; Chemoprevention; CRISPR-Cas Systems; DNA Breaks, Double-Stranded; DNA Repair; Female; Germ-Line Mutation; HeLa Cells; Humans; Indazoles; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Phthalazines; Piperazines; Piperidines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Spheroids, Cellular; Synthetic Lethal Mutations; X-ray Repair Cross Complementing Protein 1 | 2018 |
Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy-mediated drug resistance in ovarian cancer cells, xenografts, and patient-derived xenograft models.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Cell Line, Tumor; Chloroquine; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Indazoles; Mice, Nude; Mice, SCID; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Xenograft Model Antitumor Assays | 2020 |
The kinase polypharmacology landscape of clinical PARP inhibitors.
Topics: Antineoplastic Agents; Binding Sites; Cyclin-Dependent Kinases; Dyrk Kinases; HEK293 Cells; Humans; Indazoles; Indoles; Isoenzymes; Molecular Docking Simulation; Neoplasms; Phthalazines; Piperazines; Piperidines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Polypharmacology; Protein Binding; Protein Interaction Domains and Motifs; Protein Serine-Threonine Kinases; Protein Structure, Secondary; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Substrate Specificity | 2020 |
PARP inhibitors combined with ionizing radiation induce different effects in melanoma cells and healthy fibroblasts.
Topics: Apoptosis; Cell Survival; Chemoradiotherapy; Drug Interactions; Fibroblasts; G2 Phase Cell Cycle Checkpoints; Homologous Recombination; Humans; Indazoles; Melanoma; Phthalazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Primary Cell Culture; Skin; Skin Neoplasms; Tumor Cells, Cultured | 2020 |
Histone Parylation factor 1 contributes to the inhibition of PARP1 by cancer drugs.
Topics: Antineoplastic Agents; Benzamides; Benzimidazoles; Binding Sites; Carrier Proteins; Catalysis; Catalytic Domain; DNA Repair Enzymes; Humans; Indazoles; Indoles; Nuclear Proteins; Phthalazines; Piperazines; Piperidines; Poly (ADP-Ribose) Polymerase-1; Protein Binding | 2021 |
PARP Inhibitors Talazoparib and Niraparib Sensitize Melanoma Cells to Ionizing Radiation.
Topics: Cell Cycle; Cell Line, Tumor; Fibroblasts; Humans; Indazoles; Melanoma; Phthalazines; Piperidines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Radiation Tolerance | 2021 |